BUZZ-West Pharma shares rise after completing credit facility refinancing
路透社2026/10/26 21:56October 26 - ** West Pharmaceutical Services (WST.N) shares rose 3.4% in after-hours trading, to $408.18
** According to regulatory filings, the company terminated its existing 2019 credit agreement after repaying the remaining $130 million outstanding debt
** West Pharmaceutical Services (link) signed a new five-year financing agreement, which includes a $750 million revolving credit facility and a $200 million term loan
** The new financing arrangement provides greater financial flexibility for working capital, capital expenditures, acquisitions, and other corporate purposes
** The company stated that the termination of its original credit agreement did not incur any prepayment penalties
** As of the close of the previous trading day, the stock had gained 43.5% so far this year
(To facilitate non-English speakers, Reuters has automatically translated its report into several other languages. As automated translation may contain errors or lack the necessary context, Reuters does not guarantee the accuracy of automated translation and provides it only for reader convenience. Reuters accepts no responsibility for any harm or loss resulting from the use of the automated translation feature.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ - Shares of Australia's SCX.ai surge due to SpaceX partnership
Zcash co-founder releases ZIP proposal to "terminate ZCG funding channel and instead support NSM"

Citadel warns: Tech stock sell-off is just the first warning sign, AI trading offers "almost no room for error"
The sell-off in tech stocks reflects rising doubts about AI profitability, with Citadel stating that there is very little margin for error in AI trading. Grayscale noted that demand is parabolic, and capital expenditure presents a two-sided risk.
Daiwa raises Tesla's target price to $390
